Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is intended to provide evidence that zonisamide is safe and effective in the
treatment of myoclonic seizures. The total planned trial duration will be 6.5 months. After
that, subjects who have completed the study will be eligible to enroll in an open-label
extension study until zonisamide is marketed for this indication or further development in
this indication stops. This extension study will be described in a separate protocol
(E2090-E044-318).